COMPASS Pathways plc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CMPS in the last 30 days.
See all $CMPS insider activity →COMPASS Pathways' psychedelic therapy for treatment-resistant depression is nearing FDA approval, with phase III trials showing rapid and durable efficacy. The company targets a 2027 launch, citing strong payer interest, robust infrastructure, and a large unmet patient need. A PTSD program is also advancing, according to a Morgan Stanley conference transcript.
COMPASS Pathways (CMPS) presented at Morgan Stanley's conference, targeting a 2027 launch for its psilocybin-based drug COMP360. The company reported strong clinical data, FDA progress, and a ready treatment network. Shares are up 171% year-to-date, trading near a 52-week high at $14.13, with a $1.96B market cap.
FDA held meetings on psychedelic drug development and PDUFA reauthorization. Definium reported successful Phase 3 trial data for its LSD drug, aiming for FDA approval. Biopharma companies presented positive lung cancer survival data. Novartis' asset stumbles caused a 13% share price drop.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning CMPS (COMPASS Pathways plc). Coverage has skewed bullish: 8 bullish, 1 neutral, and 0 bearish.
Recent CMPS coverage spans technology, regulation and market movers.
Potential FDA approval could unlock significant market upside for CMPS.
Positive Phase III data and accelerated FDA engagement could drive the stock higher ahead of a potential 2027 launch.
Positive Phase 3 results could lift CMPS as investors anticipate FDA filing.
Regulatory focus may lift the stock.
Positive durability data may lift near‑term valuation and reduce perceived risk of the upcoming Phase 3 COMP006 readout.
AlphAI scores every news story that mentions CMPS with an AI model for sentiment and relevance, and aggregates insider trades from COMPASS Pathways plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
COMPASS Pathways' psychedelic therapy for treatment-resistant depression is nearing FDA approval, with phase III trials showing rapid and durable efficacy. The company targets a 2027 launch, citing strong payer interest, robust infrastructure, and a large unmet patient need. A PTSD program is also advancing, according to a Morgan Stanley conference transcript.
1 min readCOMPASS Pathways (CMPS) presented at Morgan Stanley's conference, targeting a 2027 launch for its psilocybin-based drug COMP360. The company reported strong clinical data, FDA progress, and a ready treatment network. Shares are up 171% year-to-date, trading near a 52-week high at $14.13, with a $1.96B market cap.
3 min readFDA held meetings on psychedelic drug development and PDUFA reauthorization. Definium reported successful Phase 3 trial data for its LSD drug, aiming for FDA approval. Biopharma companies presented positive lung cancer survival data. Novartis' asset stumbles caused a 13% share price drop.
2 min readThe FDA will hold a public hearing on psychedelic drugs' therapeutic use, part of a Trump administration push to accelerate development. The FDA has issued priority vouchers to three companies. The hearing will discuss practical issues like training and safety data. FDA officials published a framework for psychedelic drug approval, suggesting flexible trial designs. Industry executives say this could reduce regulatory delays and benefit companies like AtaiBeckley, Compass Pathways, and Definium
2 min readCOMPASS Pathways (CMPS) reported 52-week Phase 3 trial data for COMP360 in treatment-resistant depression, showing sustained efficacy and safety. The results suggest long-term symptom relief, impacting future treatment models. Analysts project significant revenue and earnings growth by 2029, with varying upside estimates. The next key catalyst is the Phase 3 COMP006 readout and regulatory progress.
2 min readCompass Pathways (CMPS) reported that its psilocybin treatment COMP360 showed sustained benefits for treatment-resistant depression in a Phase 3 trial. Shares rose 5% in pre-market trading, extending recent gains. The FDA granted a rolling NDA review, with a commercial launch targeted for 2027.
2 min readCompass Pathways (CMPS) shares rose 4% after the company released 52-week data showing lasting depression relief. Medicus Pharma announced a deal with Pfizer to advance its cancer program and strengthen its position in precision oncology, according to the company's CEO.
1 min readCompass Pathways (CMPS) selected Fluence to develop a clinician training program for its psilocybin treatment, COMP360, if approved by the FDA. The program will cover psychedelic care fundamentals, psilocybin science, and COMP360-specific topics. CMPS shares fell 6.33% following the announcement, trading at $14.21 with above-average volume.
2 min readWall Street indices fell for a third straight day, with the Dow down 0.8%, S&P 500 down 0.5%, and Nasdaq down 0.7%. Oil prices topped $100/barrel, and Treasury yields rose to 4.83%. Investors are concerned about inflation and Fed policy. Apple's event is expected to unveil a foldable iPhone. Several companies reported earnings, with mixed reactions.
4 min readCompass Pathways (CMPS) shares rose 4% after 52-week data from its Phase III study showed sustained depression relief with infrequent dosing. Analysts at Jefferies expect FDA approval, estimating a $1.5B peak sales opportunity. The company aims to complete its New Drug Application submission by Q4 2026, with a planned launch in early 2027.
2 min read
